GRN-300 is under clinical development by Greenfire Bio and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GRN-300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - WMA-1 in Solid Tumor

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRN-300 overview

GRN-300 is under development for the treatment of  endometrial cancer, triple-negative breast cancer, prostate cancer, acute myeloid leukemia (AML), diffuse large B-cell lymphoma and lung cancer. It is administered through oral route. It acts by targeting serine/threonine-protein kinase (SIK2) and serine/threonine-protein kinase (SIK3). The drug candidate is developed based on fragment-field drug design (FFDD) technology platform.
The drug candidate was under development for the treatment of solid tumors, recurrent ovarian cancer, primary peritoneal cancer and fallopian tube cancer.

See Also:

Greenfire Bio overview

Greenfire Bio (Greenfire) is a clinical-stage biopharma company that builds a diversified product pipeline by developing early-stage assets. The company’s product pipeline includes GRN-300, M-001, M-002, M-003, M-004 and PCLX-001. Its products pipeline treats for ovarian cancer, TNBC, melanoma, glioma, colorectal cancer and hepatocellular carcinoma, diffuse b-cell lymphoma (DLBCL) and acute myeloid leukemia (AML), Greenfire therapeutic area includes oncology and solid tumors. The company acquires small molecule SIK2/3 inhibitor (GRN300. Greenfire is headquartered in Austin, Texas, the US.

For a complete picture of GRN-300’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.